Thalia Therapeutics is acquiring Sanmirna Therapeutics for an initial £3.675 million and up to £13 million in milestone payments, adding the clinical-stage acute myeloid leukemia (AML) candidate miRisten and transforming the company from a preclinical platform into a clinical-stage RNA therapeutics company.
Merck KGaA has partnered with Versant Ventures to launch Saturnus Bio, a new biotech developing precision medicines for rare genetic cardiomyopathies.
UK-based TRIMTECH Therapeutics has raised an additional $14 million, bringing its total seed financing to $47 million.
Sanofi’s Cenrifki (tolebrutinib) has been approved in the EU as the first disability-targeting medicine for adults with secondary progressive multiple sclerosis (SPMS) without relapses in the previous two years.
Recent preclinical data published in Molecular Therapy suggest the company may be closer than ever to answering that question. Its platform did not emerge from a single discovery programme, but from a sequence of acquisitions that brought together the key ingredients for in vivo cell engineering: mRNA payloads, lipid nanoparticle delivery, and targeted immune-cell guidance. Across big pharma, companies are increasingly assembling in vivo CAR-T platforms piece by piece, raising a broader question about whether the next generation of cell therapy will be built in-house, or bought.
With an unusually strong fundraising trajectory, Paris-based Bionyra Pharma emerged from stealth today with financing that marks the largest life sciences biopharma Series A round in Europe this year and the largest of all time in France. The company develops next-generation biologics for immune-mediated inflammatory diseases, including inflammatory bowel disease (IBD) and atopic dermatitis.
BioArctic AB has signed a research and collaboration agreement with Eli Lilly potentially worth $1 billion, researching a new treatment combining BioArctic’s proprietary BrainTransporter technology with an undisclosed Lilly drug candidate in neurodegeneration.
The Novo Nordisk Foundation is launching a new European incubator network to turn academic discoveries in cardiometabolic disease into drug development projects, extending the broader European innovation push it set in motion earlier this year through a DKK5.5bn (€736 million) commitment to the BioInnovation Institute (BII).
Dublin’s Jazz Pharmaceuticals has inked a cancer research collaboration potentially worth more than $4 billion plus royalties with AbCellera, the Vancouver biotech backed by billionaire investor and political activist Peter Thiel.
UK antifungal specialist F2G and Japanese partner Shionogi have announced positive topline results from the global Phase III OASIS trial of olorofim in patients with invasive aspergillosis, a life-threatening fungal infection that mainly affects immunocompromised patients.